|

Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy

RECRUITINGPhase 3Sponsored by University of Campinas, Brazil
Actively Recruiting
PhasePhase 3
SponsorUniversity of Campinas, Brazil
Started2024-01-30
Est. completion2026-01-30
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06711185

Summary

Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Female
* Over 18 years old
* Breast cancer
* Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg/m2 of doxorubicin.

Exclusion Criteria:

* Contraindications for performing CMR exams, such as patients with pacemakers or cardiac defibrillators of any type, metal clips for cerebral aneurysms, cochlear implants, and ventriculoperitoneal bypass valves.
* Inability to perform CMR due to claustrophobia.
* Renal failure with a glomerular filtration rate \< 30 ml/min/1.73 m2.
* Previous history of myocardial infarction, congestive heart failure, or myocardial revascularization, whether percutaneous or surgical.
* Previous history of significant valvular heart disease.
* Previous history of cardiomyopathies.

Conditions2

Breast CancerCancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.